[endo2008]Defining an Evidence Base for Treatment and Treatment Modalities in Patients with Acromegaly
Paul M Stewart, MD FRCP FMedSci; Professor of Medicine University of Birmingham and Consultant Physician, Queen Elizabeth Hospital, Birmingham, UK
国际糖尿病网版权所有,谢绝任何形式转载,侵犯版权者必予法律追究。

专家论述 临床科研 循证视点 endo2008 作者未知 来源:未知 2008/9/28 13:11:00    加入收藏
内容概要:Acromegaly is invariably caused by a GH secreting pituitary tumour and results in significant patient morbidity and premature cardiovascular mortality. Treatment options first and foremost should reverse the disabling symptoms (headache, sweating, tiredness, paraesthesia, arthralgia, snoring) and address the pituitary tumour itself, ideally with total excision and prevention of recurrence. The last 10 years has also seen an evidence base for the biochemical follow-up and “cure” of patients with Acromegaly, with a series of retrospective follow-up studies showing normalization of mortality rates if GH can be reduced to <5 mU/L (2.5 mg/L).
 延伸阅读
注册

网友评论仅供其表达个人看法,并不表明国际糖尿病同意其观点或证实其描述。 发表评论需登陆

相关标签

Paul M Stewart  MD 
 
关于本站 | 设为首页 | 加入收藏 | 站长邮箱 | 友情链接 | 版权申明

国际糖尿病(www.idiabetes.com.cn)对刊载的所有文章、视频、幻灯、音频等资源拥有全部版权。未经本站许可,不得转载。

国际糖尿病 版权所有  2008-2010 idiabetes.com.cn  All Rights Reserved